Last reviewed 2026-05-25 · How we verify

Symasul (SULFASYMAZINE)

Phase 2 active Small molecule Quality 19/100

Symasul (generic name: SULFASYMAZINE) is a sulfasymazine drug. It is currently in Phase 2 development.

Symasul works by inhibiting the synthesis of folic acid in bacteria, which is essential for their growth and replication.

Symasul (SULFASYMAZINE) is a small molecule drug in the sulfasymazine class. Its original development is not specified, and its current owner is also unknown. The target and indications for Symasul are not provided. It is unclear if Symasul is FDA-approved or off-patent, and its commercial status is unknown. Further information on its pharmacokinetics, such as half-life and bioavailability, is also unavailable.

Likelihood of approval

17.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Anti-infectives pathway favourability +2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	SULFASYMAZINE
Drug class	sulfasymazine
Modality	Small molecule
Therapeutic area	Infectious Disease
Phase	Phase 2

Mechanism of action

Think of it like a nutrient that bacteria need to grow. Symasul blocks the production of this nutrient, making it difficult for bacteria to multiply and cause infection. This helps the body's immune system fight off the infection more effectively.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Symasul CI brief — competitive landscape report
Symasul updates RSS · CI watch RSS

Frequently asked questions about Symasul

What is Symasul?

Symasul (SULFASYMAZINE) is a sulfasymazine drug.

How does Symasul work?

Symasul works by inhibiting the synthesis of folic acid in bacteria, which is essential for their growth and replication.

What is the generic name of Symasul?

SULFASYMAZINE is the generic (nonproprietary) name of Symasul.

What drug class is Symasul in?

Symasul belongs to the sulfasymazine class. See all sulfasymazine drugs at /class/sulfasymazine.

What development phase is Symasul in?

Symasul is in Phase 2.

Drug class: All sulfasymazine drugs
Therapeutic area: All drugs in Infectious Disease

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing